BioSpace News Archive

Bausch + Lomb Buys J&J’s Dry Eye Drops for $106.5M in Expansion of OTC Business

Following last week’s $1.75 billion deal to acquire Xiidra from Novartis, Bausch + Lomb is now buying J&J’s Blink product line in move to boost its over-the-counter eye care portfolio.

July 6, 2023
·
2 min read
·
Tristan Manalac
Business

Takeda, F-star Sign Potential $1B Immuno-Oncology Agreement

The companies have signed two other pacts over the last year. In the latest deal, Takeda gains access to F-star’s platform to produce tetravalent antibodies for undisclosed oncology targets.

July 6, 2023
·
2 min read
·
Tristan Manalac
Business

Sumitomo Cuts 62 Jobs in NYC Due to Company Consolidation

The layoffs are a result of Sumitomo’s decision announced in April to combine its seven subsidiaries into one company.

July 6, 2023
·
2 min read
·
Rosemary Scott
FDA

Leqembi Wins Full FDA Approval as First Anti-Amyloid Antibody for Alzheimer’s

Thursday, Eisai and Biogen’s Leqembi also became the first disease-modifying treatment for Alzheimer’s to win traditional approval. CMS coverage is expected to begin immediately.

July 6, 2023
·
3 min read
·
Heather McKenzie
Drug Development

Safety Concerns About New Weight Loss Drugs Brew as Demand Soars

The European Medicines Agency recently flagged a safety signal related to GLP-1 receptor agonists and sent a list of questions to manufacturers including Novo Nordisk, Eli Lilly, Sanofi and AstraZeneca.

July 6, 2023
·
5 min read
·
Heather McKenzie
Drug Development

Keytruda Keeps Racking Up Approvals and Clinical Wins in 2023

The Inflation Reduction Act could put an end to blockbuster runs like that of Merck’s Keytruda, experts told BioSpace. In the meantime, the drug keeps picking up more indications and positive clinical results.

July 6, 2023
·
5 min read
·
Heather McKenzie
J&J Maintains Top Pharma Brand Ranking Despite Industry Downturn

Johnson & Johnson remains the most valuable pharmaceutical brand, according to consultancy Brand Finance, beating out all other big pharma companies by a wide margin.

July 6, 2023
·
2 min read
·
Tristan Manalac
Less Than Half of New Drug Approvals Add Therapeutic Value Over Existing Treatments: Study

The proportion of supplemental indications rated as having high therapeutic value was substantially lower than for first indications, according to a new study published Wednesday in The BMJ.

July 6, 2023
·
2 min read
·
Kate Goodwin
Business

Akamis Bio Strengthens Leadership Team with Key Executive Appointments

Akamis Bio today announced the appointment of Oliver Rosen, M.D. as Chief Medical Officer (CMO), Peter Kosa, Ph.D. as Chief Business Officer (CBO), and Samantha Bailey-Bucktrout, Ph.D. as Senior Vice President, Head of Research.

July 6, 2023
·
6 min read
Business

Amneal to Report Second Quarter 2023 Results on August 4, 2023

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2023 financial results on Friday August 4, 2023, prior to market open.

July 6, 2023
·
1 min read